ABT · News · 20260813N
Revenue Performance and Mix
ABBOTT LABORATORIES · 2026-08-13 · Importance 49 · Surprise 22 · No source text
Abbott Laboratories reported quarterly revenue of $12.59 billion, up 13% year over year. Quarterly EPS was $1.31, and the results exceeded analysts’ expectations. The digest did not provide segment-level revenue, margin, or mix details.
Key facts
- Abbott Laboratories reported recent quarterly results with EPS of $1.31 and revenue of $12.59 billion, an increase of 13% year-over-year. source
- Abbott Laboratories has provided positive fiscal 2026 EPS guidance. source
- Wolfe Research upgraded Abbott Laboratories to Outperform from Peer Perform and set a $130 price target, which suggests a 17.2% upside. source
- Institutional investors collectively own 75.18% of Abbott Laboratories' stock. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +6.1% | Abbott Laboratories reported recent quarterly results with EPS of $1.31 and revenue of $12.59 billion, an increase of 13% year-over-year. |
| net_income | unclear | realized | — | Abbott Laboratories reported recent quarterly results with EPS of $1.31 and revenue of $12.59 billion, an increase of 13% year-over-year. |
| net_income | positive | probable | — | Abbott Laboratories has provided positive fiscal 2026 EPS guidance. |